U.S. markets closed

Lipocine Inc. (LPCN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.3400-0.0200 (-1.47%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.3600
Open1.3800
Bid1.3400 x 2200
Ask1.3500 x 2900
Day's Range1.3200 - 1.3800
52 Week Range0.9610 - 2.4200
Volume653,288
Avg. Volume1,178,946
Market Cap118.309M
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.2830
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Lipocine To Present At The Raymond James Human Health Innovation Conference
    PR Newswire

    Lipocine To Present At The Raymond James Human Health Innovation Conference

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conference will be held virtually. Presentation details are below.

  • FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
    PR Newswire

    FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

    Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug Application ("IND") to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid product candidate, for the treatment of postpartum depression ("PPD") in adults.

  • Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference
    PR Newswire

    Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference

    Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference. The conference will be held virtually. Presentation details are below.